论文部分内容阅读
瑞士汽巴—嘉基公司撤销两种在印度待注册的抗感染新药的开发,即杀原虫药Satranidazoie和驱虫药Amoscanate(硝酸氰胺)。该公司说:Satranidazole已在几个国家中正在对各种原虫病患者经过进行临床试验。又说,该药具有良好的药效和临床耐受性,然而,在进一步调查在不同实验条件下,安全性和评论其药效时,发现该化合物有潜在的基因毒性,危险性/有效性之比,并不象公司所预期的那样满意。因而作出决定不再上市。据报道Amoscanate已在印度认可,但尚未在印度及世界其它地方正式上市,该公司没有透露不上市这一产品的原因。 Amoscanate在美国的钩虫患者和血吸虫病患者分别完成了临床Ⅰ期、Ⅱ期的试验工作,
Ciba-Geigi Switzerland lifted two new anti-infectives to be registered in India, the Satranidazoie and Amoscanate. The company said: Satranidazole is already undergoing clinical trials in various countries for a variety of protozoan patients. In addition, the drug has shown good efficacy and clinical tolerability. However, further investigation on the safety and commentary on its efficacy under different experimental conditions revealed that the compound is potentially genotoxic, dangerous / effective The ratio is not as satisfactory as the company expects. So a decision not to go public. Amoscanate is reportedly approved in India but not yet officially listed in India and elsewhere in the world, and the company did not reveal the reasons for not listing the product. Amoscanate hookworm patients and schistosomiasis patients in the United States completed the clinical Phase I and Phase II trials, respectively,